Itemoids

You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.

Novo

since

auto-detected in 133 stories

2 hours ago

The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.

4 days ago

Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.

6 days ago

CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.

11 days ago

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.

13 days ago

The new recommendation will significantly expand access to Wegovy on the England's NHS.
Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.

20 days ago

Novo Nordisk's exclusive hold on semaglutide - the active ingredient in popular fat-busting GLP-1 jabs such as Wegovy and Ozempic - expired last Friday.

35 days ago

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.

42 days ago

Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday.

47 days ago

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

page 1 of 14 last →|